Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

4.725 +0.265 (+5.94%)
Streaming Delayed Price Updated: 3:32 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
Why Shares of Puma Biotechnology Rose This Week
The company's CEO bought $2.5 million worth of company stock. 
Via The Motley Fool
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Releases Updated Corporate Presentation
From Puma Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
It may have benefited from positive news about another company's drug candidate. 
Via The Motley Fool
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share. 
Via Benzinga
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
 
Via Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
Via Benzinga
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
Short Volatility Alert: Puma Biotechnology, Inc.
On Tuesday, shares of Puma Biotechnology, Inc. (NASDAQ: PBYI) experienced volatile short activity. After the activity, the stock price went up +3.99% to $3.26. The overall sentiment for PBYI has been... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
Puma Biotechnology Reports Third Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology's Earnings Outlook
Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Puma... 
Via Benzinga
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
 
Via Benzinga
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.